<DOC>
	<DOCNO>NCT00579826</DOCNO>
	<brief_summary>This multi-institution double-blind placebo-controlled trial whose main objective determine 6 month letrozole ( 2.5 mg daily ) reduce proliferation assess Ki-67 high risk postmenopausal woman systemic hormone replacement therapy random periareolar fine needle aspiration ( RPFNA ) evidence hyperplasia atypia borderline atypia , minimum Ki-67 &gt; 1.5 % . The primary hypothesis proliferation expression estrogen response gene favorably modulate six month letrozole relative placebo without substantially increase hot flash worsen overall quality life .</brief_summary>
	<brief_title>Study Breast Cancer Prevention Letrozole High Risk Women</brief_title>
	<detailed_description>Subsequent 6 month RPFNA assessment biomarkers , toxicity quality life assessment , woman may receive optional open-label letrozole additional 6 month , follow third RPFNA biomarker</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal woman high risk development breast cancer On stable dose hormone replacement therapy cytomorphologic evidence hyperplasia +/ atypia Ki67 expression &gt; 1.5 % benign breast epithelial cell acquire RPFNA Serum level 25OH vitamin D least 30 ng/ml prior study entry Willing repeat random periareolar fine needle aspiration ( RPFNA ) mammogram 6 month 12 month ( participate open label portion study ) follow initiation study drug Prior history osteoporosis osteoporotic fracture . Prior history invasive breast cancer invasive cancer within five year date study entry . Current chronic use cyclooxygenase2 ( COX2 ) specific inhibitor NSAIDs Receiving treatment rheumatoid arthritis fibromyalgia Current history poorly control migraine perimenopausal symptom Currently receive investigational agent . Receipt 6 month aromatase inhibitor ( anastrozole , exemestane , letrozole , etc . ) time past .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>